Work on gene therapy is showing significant progress for restoring muscle strength and prolonging lives in dogs with a previously incurable, inherited neuromuscular disease. UW Medicine Institute for Stem Cell and Regenerative Medicine scientists are leading the multi-institutional research effort.
The disease arises from a mutation in genes that normally make a protein, called myotubularin, essential for proper muscle function. Puppies with this naturally occurring mutation exhibit several features of babies with the same defective gene. The rare disorder, called myotubular myopathy, or MTM, affects only males. It causes fatal muscle wasting. Both dogs and boys with the disease typically succumb in early life due to breathing difficulties.
For decades, researchers have struggled to find suitable treatments for genetic muscle diseases like this one. Four collaborating research groups in the United States and France found a way to safely replace the disease-causing MTM gene with a healthy gene throughout the entire musculature of affected dogs.
Their most recent findings were published online this week in Molecular Therapy.
Their paper reports that diseased dogs treated with a single infusion of the corrective therapy were indistinguishable from normal animals one year later.
The relationship of dosage to survival in canine studies of gene therapy for a muscle-wasting disorder
“This regenerative technology allowed dogs that otherwise would have perished to complete restoration of normal health,” said Dr. Martin K. “Casey” Childers, UW Medicine researcher and physician. Childers is a professor of rehabilitation medicine at the University of Washington School of Medicine and co-director of the Institute for Stem Cell and Regenerative Medicine.
Gene therapy holds the promise to treat many inherited diseases. To date, this approach has not been widely translated into treatment of skeletal muscle disorders.
“We report here a gene therapy dose-finding study in a large animal model of a severe muscle disease where a single treatment resulted in dramatic rescue,” said Childers. The findings demonstrate potential application across a wide range of diseases and broadly translate to human studies. The data supports the development of gene therapy clinical trials for myotubular myopathy, the researchers concluded.
University of Washington researchers David Mack, Melissa Goddard, Jessica Snyder, Matthew Elverman, and Valerie Kelly co-authored the report, “Systemic AAV8-mediated gene therapy drives whole-body correction of myotubular myopathy in dogs.” This study was conducted in collaboration with Harvard University, Medical College of Wisconsin, Virginia Tech, INSERM, and Genethon.
This work was supported in part by United States National Institutes of Health grants R21 AR064503, R01 HL115001, K08AR059750 K08 HL111148, R01 AR044345; Senator Paul D Wellstone Muscular Dystrophy Cooperative Research Center; Muscular Dystrophy Association; Association Française contre les Myopathies; Myotubular Trust; Where There’s a Will There’s a Cure; Joshua Frase Foundation, Peter Khuri Myopathy Research Foundation; Audentes Therapeutics and Solid GT.
For more stories, click here >>